The IPO Buzz: Scribe Therapeutics (SCTX Proposed) Sets Terms for $100 Million IPO

Scribe Therapeutics (SCTX Proposed), an Eli Lilly-backed Phase 1 biotech  developing drugs to lower cholesterol and triglyceride levels, launched its $100.1 million IPO early today – with plans to price it later this week. The company, based in Alameda, California, is offering 7.15 million shares at a price range of $13.00 to $15.00 to raise $100.1 million, if priced at the $14.00 mid-poin..

Read more July 20, 2026

IPO Calendar

Company Symbol proposed Lead Managers Shares (Millions) Price Low Price High Est. $ Volume Expected to Trade SCOOP Rating Rating Change
Southern Cross Acquisition I Corp. NCOU D. Boral Capital (ex-EF Hutton) 10.0 10.00 10.00 $ 100.0 mil 7/21/2026 Tuesday S/O S/O
Scribe Therapeutics, Inc. SCTX Leerink Partners/Goldman Sachs/Guggenheim Securities/Wells Fargo Securities 7.2 13.00 15.00 $ 100.1 mil 7/24/2026 Friday S/O S/O
BW Industrial Holdings BWGC Eddid Securities USA 2.6 6.00 7.00 $ 17.1 mil 7/27/2026 Week of S/O S/O
Read more

Last 100 IPOs - July 19, 2026

Number of IPOs priced : 100
Number Up: 54
Number Down: 43
Number Unchanged: 3
Percentage Change From Issue Price: 6.01%
Percentage Change for The Nasdaq Composite 35.22%

2026 IPO Scorecard - July 19, 2026

Number of IPOs priced (Excluding 127 units) : 98
Number Up: 53
Number Down: 42
Number Unchanged: 3
Total Return From Issue Price: 5.66%
The Nasdaq Composite Index YTD % Change 35.22%